Inogen Announces Fourth Quarter and Full Year 2019 Financial Results and Updates 2020 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Inogen (INGN) Misses Q4 EPS by 16c, Revenues Miss; Offers FY20 Revenue Guidance Below Consensus
February 25, 2020 4:43 PM ESTInogen (NASDAQ: INGN) reported Q4 EPS of ($0.06), $0.16 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $78.9 million versus the consensus estimate of $86.42 million.
Fourth Quarter 2019 Highlights
Total revenue of $78.9 millionInogen One G5® units accounted for over 40% of total unit volume in the periodLimited launch of the Inogen Tidal Assist® Ventilator (TAV®) product in December 2019As of December 31, 2019, the Company had 329 inside direct-to-consumer sales representatives and 17 outside physician sales representativesWhile 2019 was a challenging year, revenue increased 8.2% over the prior year, excluding the... More
